Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Oruka Therapeutics Inc.

In a report released today, Michael Yee from UBS maintained a Buy rating on Oruka Therapeutics, with a price target of $75.00. According to TipRank...

UBS Sticks to Its Buy Rating for Oruka Therapeutics (ORKA)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on HeartFlow, Inc. (HTFL), Taysha Gene Therapies (TSHA)...

Analysts Are Bullish on These Healthcare Stocks: HeartFlow, Inc. (HTFL), Taysha Gene Therapies (TSHA)

Oruka Therapeutics, Inc. ($ORKA) announced an update on their ongoing clinical study. The study, titled “Phase 1, First-in-human, Double-Blind, Pla...

ORKA-001 Phase 1 Completion: What Oruka’s First-in-Human Milestone Means for Investors

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Citius Oncology (CTOR – Research Report) and Oruka T...

Analysts Offer Insights on Healthcare Companies: Citius Oncology (CTOR) and Oruka Therapeutics (ORKA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Denali Therapeutics (DNLI – Research Report) and Oru...

Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI) and Oruka Therapeutics (ORKA)

In a report released yesterday, Yatin Suneja from Guggenheim reiterated a Buy rating on Oruka Therapeutics, with a price target of $60.00. The comp...

Oruka Therapeutics (ORKA) Receives a Buy from Guggenheim

Jefferies analyst Roger Song maintained a Buy rating on Oruka Therapeutics today and set a price target of $45.00. Song covers the Healthcare secto...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ORKA	$61.76	+1.91%	1.21M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ORKA	$61.76	+1.9%	1.21M
3
4
5
6

ORKA

ORKA

No Data Available

Get Oruka Therapeutics Inc. Data in Excel

Get Oruka Therapeutics Inc. Data in Excel